My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC - Episode 10
Optimizing Treatment in Advanced RCC
Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.
- In your experience, what is the optimal duration of treatment with len + pembro in patients with advanced renal clear cell carcinoma?
- How do you monitor patients and make decisions around continuing or discontinuing treatment in clinical practice?
- When do you consider switching therapies versus dose reductions to maintain treatment duration?
Related Content:
